Baxter announced it had completed its acquision of Somatogen
On May 5, 1998, Baxter announced it had completed its acquision of Bulder, Colorado-based of Somatogen in a stock transaction worth about $189 million.
Somatogen was a developer of a genetically engineered blood-substitute.
Tags:
Source: Chicago Tribune
Credit: